Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers. (2016)
Attributed to:
The UK Centre for Tobacco and Alcohol Studies (UKCTAS)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/add.13438
PubMed Identifier: 27262594
Publication URI: http://europepmc.org/abstract/MED/27262594
Type: Journal Article/Review
Volume: 111
Parent Publication: Addiction (Abingdon, England)
Issue: 8
ISSN: 0965-2140